ClinicalTrials.gg
RecruitingNCT03803423Updated Nov 10, 2025

Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors

An interventional study of The Donor App in End Stage Renal Disease and End Stage Liver Disease, sponsored by Johns Hopkins University. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Nov 2017, registered Jan 2019).
  • Started Nov 2017; still recruiting 8 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Kidney Failure, Chronic by Johns Hopkins University — 2 open to participants now, 2 under way, none of them phase 3. Kidney Failure, Chronic · Johns Hopkins University.

Planned enrollment
Largest of 12
1,000 · median 28
Started
2017
the only one that year
No phase
7 of 13
2 open now
Registered
10th of 13
by date

Among the 13 studies in Kidney Failure, Chronic by Johns Hopkins University, this one has the largest planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2017, is one of 7 with no phase, and was the 10th registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

2 of the 13 studies in Kidney Failure, Chronic by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Kidney Failure, Chronic by Johns Hopkins University, or all of them as a file.
02

Study summary

This study utilizes a web-based application to help patients on the organ transplant waitlist communicate patient's need for a living donor via social media and provide interested potential donors the opportunity to engage with the evaluation process.

Read the detailed description

Barriers to identifying a live donor include lack of education and hesitance to initiate a conversation about live donation. For these reasons, many transplant candidates are hesitant to discuss candidate's illness and are therefore reluctant to pursue live donor transplantation. The investigators hypothesize that utilization of social media to spread awareness about candidate's illness and candidate's need for a live donor will enable many transplant candidates to successfully identify live donors. In this study, participants will use a novel web-based application, called the "Donor App", to create and share candidate's story via Facebook and other social networks to assist in the search for a live donor.

03

Conditions studied

  • End Stage Renal Disease
  • End Stage Liver Disease

Keywords

  • Live Donor Transplant
  • Social Media
  • Advocacy
  • Education
  • Living Donation
  • The Donor App
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • On the kidney-only or liver-only transplant waiting list at a collaborating center

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years of age
  • Not on the kidney or liver transplant waiting list
  • On multiple organ transplant waiting lists
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    The Donor App

    Select physicians and research staff from about 15 transplant hospitals will be given access to distribute the application to patients who the above people feel could benefit from the application. After obtaining informed consent, an approved member of the study team will enter the participant's name, contact info, and organ needed into the Donor App's secure management portal to send an email or text message with a unique and protected invitation link to the participant. Using this link the participant will be allowed to use the Donor App indefinitely.

    Other: The Donor App

Interventions

  • OtherThe Donor App

    The Donor app is a web-based application that helps transplant candidates tell the candidate's story via social media in the hopes of identifying an appropriate living donor. Sample stories created using the Donor App can be found at www.thedonorapp.com.

06

What researchers measure

Primary outcomes

  1. Potential donors identified

    Number of potential live donors that come forward to the transplant center on behalf of the participant.

    Time frame: Up to 5 years

  2. Live donor transplantation

    Number of participants that receive a live donor transplant.

    Time frame: Up to 5 years

Secondary outcomes

  1. App utilization as assessed by number of participants with story completion and posting in the donor app

    The extent of a participants story completion and posting will be recorded internally by the Donor App. The number of participants that complete stories and post will be counted to assess app utilization.

    Time frame: Up to 5 years

  2. The Donor App Implementation

    Success of the Donor App across multiple institutions will be tracked by the number of participants enrolled and invited to use the app at each institution.

    Time frame: Up to 5 years

07

Study locations

5 of 6 sites recruiting
  • Scripps Green Hospital
    San Diego, California 92037, United States
    Enrolling by invitation
  • Yale University
    New Haven, Connecticut 06520, United States
    Enrolling by invitation
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    Not yet recruiting
    • Sherri Loeb, BSN · Contact
  • Maine Medical Center
    Portland, Maine 04102, United States
    Enrolling by invitation
  • The Johns Hopkins Hospital
    Baltimore, Maryland 21218, United States
    Recruiting
    • Andrew Cameron, MD PhD · Contactdonorapp@jhu.edu · 443-287-0134
    • Andrew Cameron, MD PhD · Principal investigator
  • Washington University in St. Louis
    St Louis, Missouri 63110, United States
    Enrolling by invitation
08

References and documents

Publications

  • Kumar K, King EA, Muzaale AD, Konel JM, Bramstedt KA, Massie AB, Segev DL, Cameron AM. A Smartphone App for Increasing Live Organ Donation. Am J Transplant. 2016 Dec;16(12):3548-3553. doi: 10.1111/ajt.13961. Epub 2016 Aug 10. PubMed 27402293 ↗
  • Bramstedt KA, Cameron AM. Beyond the Billboard: The Facebook-Based Application, Donor, and Its Guided Approach to Facilitating Living Organ Donation. Am J Transplant. 2017 Feb;17(2):336-340. doi: 10.1111/ajt.14004. Epub 2016 Sep 7. PubMed 27501516 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2017 (actual). Primary completion is estimated for Nov 2026, 108 months after the start.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 108 months is above that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2019
First posted
Jan 14, 2019
StartActual
Nov 27, 2017
Primary completionEst.
Nov 27, 2026
CompletionEst.
Nov 27, 2026
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03803423
Responsible party
Sponsor
First posted
Jan 14, 2019
Start date
Nov 27, 2017
Primary completion
Nov 27, 2026 (estimated)
Completion
Nov 27, 2026 (estimated)
Last update
Nov 10, 2025

Study contacts

Andrew Cameron, MD PhD
Contact
donorapp@jhu.edu
4432870134
Andrew Cameron, MD PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion